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On the assumption that Asp-217 of a Citrobacter f eundii cephalosporinase forms a salt-bridge with the conserved Lys-67, Asp-217 was changed 
to glutamic acid, threonine or lysine. The mutant enzymes retained about the same level of activity as that of the wild-type enzyme, and the participa- 
tion of Asp-217 in the salt-bridge was ruled out. However, the mutations resulted in an increase in hydrolytic activity toward oxyiminocephalo- 
sporins such as cefuroxime, cefmenoxime and ceftazidime, suggesting a possible mechanism of the bacterial resistance to the novel ,&Iactams by 
a single mutation in cephalospo~na~s. 
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1. INTRODUCTION 
Cephalosporinases are mainly responsible for the 
high levels of resistance to traditional cephalosporins of 
Gram-negative bacteria [ 11 and most of the enzymes aie 
class C ,&lactamases, according to Ambler’s classifica- 
tion [2]. A ceph~osporinase produced by Citrobacter 
freundii GN346 is a species-specific &lactamase with 
the substrate profile of a typical ceph~osporin~e and 
its enzymological properties have been extensively in- 
vestigated by us [3-61. 
On the basis of the crystal structure of the class A J?- 
lactamase of Staphylococcus aweus PC1 I Herzberg and 
Moult [7] suggested a salt-bridge interaction between 
the conserved Lys-73 and Glu-166 in the class A en- 
zyme, and the significant role of Glu-166 in the catalytic 
reaction was confirmed by Madgwick and Waley [8]. 
Lys-73 of the class A enzymes is situated at a position 
close to catalytic residue Ser-70 and corresponds to 
Lys-67 of the C. freundii cephalosporinase. On the 
basis of the comparative method proposed by Doris et 
al. [9], we assumed that Asp-217 of the C. freundii 
cephalosporinase corresponds to Glu-166 of the class A 
enzymes. We changed Asp-217 to glutamic acid, 
threonine and lysine in order to confirm this assump- 
tion. Although the result was contrary to our expecta- 
tion, we found it an interesting fact that a single amino 
acid replacement at this position results in extension of 
the enzyme’s substrate spectrum to methoxyimino- 
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cephalosporins. In this paper, we report the properties 
of the mutant cephalosporinases. 
2. MATERIALS AND METHODS 
2.1. Eseherichia coli strains and plasmids 
E. cofi TGl [lo], a derivative of K12, was empfoyed for DNA 
technology and for measuring the drug resistance of cells bearing the 
mutant ceph~osporinase genes. i?. coii AS226-51 is an ampD mutant 
of C600, which also has a deletion mutation in ampC. AS22651 was 
used as a host cell for purification of the mutant enzymes. Plasmid 
pCFC-1 is a derivative of pHSG398, into which the wild-type 
c~ha~osporinase gene from C. freundii GN346 was inserted [5]. 
M13-CFC-I was derived from M13mp18 [ll] and also carries the 
wild-type enzyme gene. pHSG398 carrying the mutant cephalo- 
sporinase genes is termed pCFC-D217E, pCFCD217T and pCFC- 
D217K, respectively, which are given the general name, pCFC- 
D217X. X denotes glutamic acid, threonine or &sine. The mutant 
genes are named using a one-letter amino acid code, i.e. D217E means 
a mutant gene in which aspartic acid-217 was changed to glutamic 
acid. 
2.2. Media, chemicals and enzymes 
For the transformation and transfection experiments, 2x YT broth 
1121 and YT agar [12] were employed. Heart infusion agar (Eiken 
Chemical Co., Tokyo, Japan) was used for measuring the bacterial 
susceptibility to antibiotics. For enzyme preparation, bacteria were 
grown in 2 x YT broth. The antibiotics used in this study were kindly 
provided by the following pharmaceutical companies: benzylpeni- 
cillin (Meiji Seika Co., Tokyo, Japan); carbenicillin (Fujisawa Phar- 
maceutical Co., Osaka, Japan); cephalothin and ceph~o~dine 
(Shionogi Pharmaceutical Co., Osaka, Japan); cefuroxime and cef- 
tazidime (Nihon Glaxo Co., Tokyo, Japan); cefmenoxime (Takeda 
Chemical Industries, Osaka, Japan); cefoxitin and imipenem (Merck 
Sharp and Dohme Research Laboratories, NJ, USA); aztreonam 
(Eisai Co., Tokyo, Japan); and chloramphenicol (Yamanouchi Phar- 
maceutical Co., Tokyo, Japan). [Lu-32P]dCTP and the in vitro 
mutagenesis kit were purchased from Amersham Inc. (Buckingham- 
shire, UK). Ml3 sequencing kit and enzymes for DNA technology 
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were purchased from Boehringer Mannheim CmbH, Takara Shuzo 
Co. (Kyoto, Japan), and Nippon Gene Co. (Toyama, Japan). 
2.3. Oi~gonuc~eot~d~ and site-directed mutagenesis 
GligonucIeotides, 17- or 18-mer, were synthesized using a DNA 
synthesizer model 380B (Applied Biosystems, CA, USA). Site- 
directed mutagenesis was performed by the method of Eckstein [13]. 
The mutant genes were sequenced to confirm the desired exchange in 
the nucleotide sequence by the chain-termination method 1141 using a 
specific oligonucleotide primer. 
2.4. ~-Lacfamase p~rificution, @-lactamnse activity assay and kinetic 
parameters 
E. coli AS22651 cells carrying pCFC-D217X were grown overnight 
in 2 x YT medium at 37°C. The medium contained chloramphenicol 
(30 @g/ml) and cephalothin (50 #g/ml) to ensure that the plasmid 
would not be lost. The preculture was then diluted with a 40-fold 
volume of fresh medium, followed by growth at the same temperature 
under aeration until the middle of the logarithmic phase. BLactamase 
activity in the bacterial cells was measured after sonic treatment of the 
cells. For further purification, the procedures established for purifica- 
tion of the wild-type enzyme were applied [6]. The mutant enzyme 
mediated by pCFC-D217X was extracted from the E. coti cells and 
purified to homogeneity by adsorption and elution on a CM- 
Sephadex C-50 column, and gel filtration on a Sephadex G-75 col- 
umn, and its purity was confirmed by SDS gel-electrophoresis. ,8- 
Lactamase activity was assayed by a microiodometric method [15] 
with slight modifications, and a ultraviolet spectrophotometric 
method [ 161. One unit of the enzyme was defined as the amount of en- 
zyme which hydrolyzed 1 pmol of substrate at pH 7 and 30°C. The 
kinetic parameters, K,,, and Ki, were determined by the procedures 
reported previously [16]. 
2.5. Antibiotic susceptibility testing 
The bacterial susceptibility to antibiotics was measured by the serial 
agar dilution method, according to the procedure described previous- 
ly [I]. The susceptibility was expressed as the minimum inhibitory 
concentration of a drug &g/ml). 
3. RESULTS AND DISCUSSION 
3.1. Conversion of Asp-217 in the C. freundii 
cephalosporinase to glutamic acid, threonine and 
lysine, and expression of the mutant genes in 
E. coli 
Asp-217 of the C. freundii cephalosporinase was con- 
verted into glutamic acid, threonine or lysine according 
to Eckstein’s method using M13-CFC-I as a template. 
Mutant cephalosporinase genes were screened by DNA 
Table II 
Substrate profiles of the wild and mutant cephalosporinases 
E. roli strains Substrate profiles (relative I’,,$ 
GET CER CXM CMX CA2 
TGl/pCFC-l(wild) 100 928 0.006 0.001 <3x 1o-4 
TGl/pCFC-D217E 100 600 0.10 0.04 0.11 
TGl/pCFC-D217T 100 627 0.03 0.01 0.01 
TGL’pCFC-D217K 100 1064 0.16 0.04 0.20 
a,&Lactamase activity for cephaloridine and cephalothin as the 
reference was measured by the ultraviolet spectrophotometric method 
and the V,,, values were determined by using the integrated 
Lineweaver-Burk plot analysis [19]. The relative V,,,,, values for 
cefuroxime, cefmenoxime, ceftazidine and cephalothin as reference 
were determined by the microiodome~ic method with the saturated 
substrate concentrations. The relative V,,, value is expressed as a 
percentage of that in the case of hydrolysis of cephalothin. The ab- 
breviations used for cephalosporins are the same as in Table I 
sequencing, and recioned into pHSG398. The resulting 
plasmids, pCFC-D217E, pCFCD217T and pCFC- 
D217K, carry the mutant genes coding the mutant en- 
zymes with Glu-217, Thr-217 and Lys-217, respectively. 
These plasmids and pCFC-1 were introduced into E. 
coli TGl cells by tr~sformation, and the transfor- 
mants were examined as to their susceptibility to p” 
lactam antibiotics and chloramphenicol (Table I). 
Chloramphenicol resistance is a genetic marker from 
the vector plasmid, pHSG398. The transformants, con- 
trary to our expectation, retained high levels of 
resistance to traditional cephalosporins such as 
cephalothin and cephaloridine. There were no signifi- 
cant decreases in the MICs of penicillins, a carbapenem 
(imipenem) and a monobactam (aztreonam). More- 
over, the MICs of cefuroxime in the case of the cells 
producing the Glu-217 and Lys-217 enzymes were 4-8 
times higher than that in the case of the wild-type en- 
zyme producer. Cefuroxime, a prototype of oxyimino- 
cephalosporins, is known to be stable as to hydrolysis 
by many ,&lactamases [17,18]. These results are in 
agreement with the &lactamase activity found (Table 
I). No marked differences in the activity were observed 
between cells carrying the wild-type and mutant genes. 
Table I 
B-Lactamase activity of E. coli TGI strains carrying the wild and mutant genes and the levels of resistance to antibiotics of the strains 
E. coli strains ,&Lactamase activitya 
(units/mg protein) 
MIC +g/ml)b 
CET CER CFX CXM CMX CA2 APC CPC IPM AZT CM 
TGl/pCFC-l(wiid~ 1.5 1600 200 100 50 3.1 12.5 200 100 12.5 6.3 >50 
TGl/pCFC-D217E 1.6 1600 100 100 200 3.1 12.5 200 200 12.5 6.3 >50 
TGl/pCFC-D217T 1.7 1600 200 200 50 3.1 12.5 100 200 12.5 6.3 >.50 
TGl/pCFC-D217K 1.3 1600 100 100 400 3.1 12.5 100 200 12.5 6.3 >50 
TGI <80x lO-3 6.3 3.1 1.6 <0.4 0.4 1.6 6.3 12.5 co.2 6.3 
a &Lactamase activity in sonically disrupted cells was measured by the microiodometric method with cephalothin as the substrate and 
the activity was expressed as units per mg of bacterial protein 
b The antibiotics used were: CET, cephalothin; CER, cephaloridine; CFX, cefoxitin; CXM, cefuroxime; CMX, cefmenoxime; CAZ, 
ceftazidime; APC, ampicillin; CPC, carbenicillin; IMP, imipenem; AZT, aztreonam; CM, chloramphenicol 
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Table III 
Km and Ki values of Slactams for the wild and mutant ceDh&osoorinases 
Kinetic parameters’ @-Lactams Cephalosporinase 
Wild D217E D217T D217K 
Km GM) cephalothin 19 29 49 65 
cephaloridine 410 692 822 2180 
4 GM) cefuroxime 0.01 0.07 0.01 0.07 
cefmenoxime 0.02 0.08 0.02 0.3 
ceftazidime 1 7 3 28 
a The lu, values were obtained from Lineweaver-Burk plots of the initial rate 
of hydrolysis, using the ultraviolet spectrophotometric method. The Ki values 
for inhibition by the methoxyimino-cephalosporins of the enzymes were 
determined with cephalothin as the substrate by the microiodometric method 
3.2. Substrate profiles of the mutant enzymes and 
their kinetic properties 
The oxyimino groups in the side-chain at position 7 
of the cephalosporin nucleus are quite commonly 
employed today for new cephalosporins, because these 
side-chain structures confer stability to many P- 
lactamases on the antibiotics. Although the mutant en- 
zymes conferring the cefuroxime resistance on the 
bacterial cells were obtained by means of site-directed 
mutagenesis in vitro, a similar evolutionary process in 
nature is quite possible because such a mutation can be 
induced by a single amino acid replacement. In order to 
compare the mutant enzymes with the wild-type enzyme 
in more detail, the 3 mutant enzymes were extracted 
from E. coli AS226-51 and purified to homogeneity. 
The substrate profiles of the wild-type and mutant en- 
zymes are compared in Table II. A remarkable increase 
in the hydrolytic activity toward the oxyimino- 
cephalosporins tested was observed in the case of the 
mutant enzymes, particularly the Lys-217 and Glu-217 
enzymes. The relative V,, values for cefuroxime, 
cefmenoxime and ceftazidime were S-27, 10-40 and 
more than 33-667 times that of the wild-type enzyme, 
respectively. These findings, together with the results in 
Table I, excluded a possibility that Asp-217 participates 
in the hypothetical salt-bridge. The lu, or Ki values of 
the enzymes for two traditional cephalosporins and 3 
oxyimino-cephalosporins are shown in Table III. The 
&, value for cephaloridine, a zwitterionic compound, 
was greatly increased by the conversion of Asp-217 into 
a basic amino acid, lysine, suggesting an interaction 
between the residue and the substrate. The replacement 
of Asp-217 by lysine and glutamic acid also resulted in 
a decrease in the affinity of the enzyme for oxyimino- 
cephalosporins. These results indicate that an acidic 
amino acid residue at position 217 is not essential for 
the catalytic reaction, but position 217 may be located 
in or close to the active site pocket, and has an effect 
upon the substrate profile. Recently, the three- 
dimensional structure of a cephalosporinase from a 
~itrobacter freundii strain was reported by Ofner et al. 
[20]. They provided an interesting hypothesis as to the 
role of Ser-64, Lys-67, Tyr-150 and Lys-315 in the 
catalysis and the contribution of Asn-152, Ser318 and 
Thr3 19 to the aztreonam binding. However, it was dif- 
ficult to speculate the role of the Asp-217 region from 
their crystallographic analysis. 
In spite of increased hydrol~i~ activity toward cef- 
tazidime and cefmenoxime, the MICs of the two 
cephalosporins for the cells producing the mutant en- 
zymes were not aftered. No probable explanation for 
such a result can be offered at the present time; 
however, this result may be attributable in part to the 
higher antibacterial activity of these third generation 
cephalosporins. 
Recently, plasmid-mediated class A &lactamases 
with extended substrate spectra for oxyimino-cephalo- 
sporins and aztrenam were discovered in clinical iso- 
lates resistant to these new ,&lactams [21-253. These 
novel class A P-lactamases were revealed to originate 
from SHV-1 P-lactamase or TEM-2 fl-lactamase and 
differ from their ancestors in only one or two amino 
acid residues [24,26,27]. However, in the case of these 
class A ,!$lactamases, the extension of the substrate 
spectra was attributed to marked increase in their af- 
finity for the new fi-lactams. Our findings reported in 
this paper may indicate the possible development of 
class C ,&lactamases against oxyimino-cephalosporins 
through chromosomal gene mutation in nature. 
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